Moxifloxacin Safety
نویسندگان
چکیده
منابع مشابه
Moxifloxacin Safety
BACKGROUND Moxifloxacin, a fluoroquinolone antibiotic, is used for the treatment of respiratory tract, pelvic inflammatory disease, skin, and intra-abdominal infections. Its safety profile is considered favorable in most reviews but has been challenged with respect to rare but potentially fatal toxicities (e.g. hepatic, cardiac, or skin reactions). OBJECTIVE To analyze and compare the safety ...
متن کاملReassuring Safety Profile of Moxifloxacin
NOTE. Data from clinical trials are from [3]; data from postmarketing observationalstudies (PMOS) are on file. ADR, adverse drug reaction. Reprints or correspondence: Dr. Vladimir Krčmery, St. Elizabeth and University of Trnava Cancer Institute, Heyduková 10, 812 50 Bratislava, Slovak Republic ([email protected]). Clinical Infectious Diseases 2001; 32:1110–2 2001 by the Infectious Diseases Soci...
متن کاملUpdate on the Cardiac Safety of Moxifloxacin
Cardiac safety was compared in patients receiving moxifloxacin and other antimicrobials in a large patient population from Phase II-IV randomized active-controlled clinical trials. Moxifloxacin 400 mg once-daily monotherapy was administered orally (PO) or sequentially (intravenous/oral, IV/PO). Across 64 trials, 21,298 patients received PO therapy (10,613 moxifloxacin, 10,685 comparators) while...
متن کاملEfficacy and safety of prophylactic intracameral moxifloxacin injection in Japan.
PURPOSE To report endophthalmitis rates after cataract surgery and the incidence of complications after intracameral moxifloxacin injection. SETTING Nineteen clinics in Japanese institutions. DESIGN Retrospective survey cohort study. METHODS The number of surgeries and endophthalmitis cases in the past 4 years before and after the introduction of intracameral moxifloxacin was evaluated. T...
متن کاملEfficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
BACKGROUND Community acquired pneumonia (CAP) is a major cause of morbidity, hospitalization, and mortality worldwide. Management of CAP for many patients requires rapid initiation of empirical antibiotic treatment, based on the spectrum of activity of available antimicrobial agents and evidence on local antibiotic resistance. Few data exist on the severity profile and treatment of hospitalized...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drugs in R&D
سال: 2012
ISSN: 1174-5886,1179-6901
DOI: 10.2165/11634300-000000000-00000